Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01.

Research in mice identifies protein responsible for regulating gut movement in response to pressure, exercise, and ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

The FDA has granted approval for the IND application of Everest Medicines’ tumour-associated antigen (TAA) vaccine, EVM14.

A novel approach using native mass spectrometry has significantly advanced the understanding of stabilization mechanisms of ...

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals' etrasimod in ulcerative colitis (UC) when it acquired the company earlier this year, and the gamble ...

Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...